[
  {
    "id": "Q001",
    "stem": "A 62-year-old postmenopausal patient with ER+/HER2– breast cancer and an Oncotype DX recurrence score of 12 asks if she needs chemotherapy. What is the most appropriate recommendation?",
    "choices": [
      "Adjuvant chemotherapy followed by aromatase inhibitor therapy",
      "Endocrine therapy alone with an aromatase inhibitor",
      "Endocrine therapy combined with CDK4/6 inhibitor",
      "Observation only"
    ],
    "answerIndex": 1,
    "rationale": "For postmenopausal, node-negative ER+/HER2– disease with low RS (≤25), endocrine therapy alone is appropriate; chemotherapy adds no meaningful benefit.",
    "wrongAnswerNotes": {
      "Adjuvant chemotherapy followed by aromatase inhibitor therapy": "Overtreatment for a low RS in a postmenopausal, node-negative patient.",
      "Endocrine therapy combined with CDK4/6 inhibitor": "Reserved for higher-risk or metastatic settings, not standard adjuvant low-risk.",
      "Observation only": "Endocrine therapy remains indicated even with low genomic risk."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "cdk4/6 inhibitor",
      "endocrine therapy",
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q002",
    "stem": "During a clinical breast exam, dimpling of the skin becomes more pronounced when the patient presses her hands firmly on her hips. This finding is most consistent with:",
    "choices": [
      "Pectoral muscle contraction revealing skin tethering",
      "Axillary lymph node involvement",
      "Localized edema due to infection",
      "Benign fibrocystic change"
    ],
    "answerIndex": 0,
    "rationale": "Pectoral contraction can accentuate tethering from tumor involvement of Cooper’s ligaments, revealing dimpling.",
    "wrongAnswerNotes": {
      "Axillary lymph node involvement": "Does not typically change skin movement during contraction.",
      "Localized edema due to infection": "May cause swelling/erythema, not retraction with contraction.",
      "Benign fibrocystic change": "Can be tender/lumpy but not classically tethered."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "physical exam"
    ]
  },
  {
    "id": "Q003",
    "stem": "A patient treated with doxorubicin (Adriamycin) is scheduled to begin a new chemotherapy cycle. Which pre-treatment assessment is essential?",
    "choices": [
      "Echocardiogram or MUGA scan to assess ejection fraction",
      "Bone density test",
      "Liver ultrasound",
      "PET-CT for restaging"
    ],
    "answerIndex": 0,
    "rationale": "Anthracyclines carry cardiotoxic risk; baseline and periodic LVEF assessment is required.",
    "wrongAnswerNotes": {
      "Bone density test": "Pertinent for aromatase inhibitors, not anthracyclines.",
      "Liver ultrasound": "Not routine before cycles without clinical suspicion.",
      "PET-CT for restaging": "Not indicated absent signs of progression."
    },
    "domain": "Nursing Practice",
    "tags": [
      "anthracycline",
      "cardiotoxicity",
      "ultrasound"
    ]
  },
  {
    "id": "Q004",
    "stem": "A 45-year-old premenopausal woman with ER+/PR+ breast cancer experiences hot flashes and mood changes after starting tamoxifen. What education should the nurse provide?",
    "choices": [
      "Hot flashes are common and may improve; avoid strong CYP2D6-inhibiting SSRIs like paroxetine.",
      "These symptoms indicate tamoxifen resistance and require urgent evaluation.",
      "Hold tamoxifen for two weeks and restart at half dose.",
      "Switch to an aromatase inhibitor."
    ],
    "answerIndex": 0,
    "rationale": "Vasomotor and mood symptoms are common; avoid potent CYP2D6 inhibitors that can reduce active metabolite formation.",
    "wrongAnswerNotes": {
      "These symptoms indicate tamoxifen resistance and require urgent evaluation.": "They are expected side effects, not failure.",
      "Hold tamoxifen for two weeks and restart at half dose.": "Dose reduction is not standard; manage side effects instead.",
      "Switch to an aromatase inhibitor.": "AIs require postmenopausal status or OFS."
    },
    "domain": "Nursing Practice",
    "tags": [
      "aromatase inhibitor",
      "chemoprevention",
      "endocrine therapy",
      "oncologic emergency",
      "symptom management",
      "tamoxifen"
    ]
  },
  {
    "id": "Q005",
    "stem": "A 38-year-old presents with peau d’orange, warmth, and erythema of the left breast that persist despite antibiotics. Which diagnostic test is most appropriate?",
    "choices": [
      "Punch biopsy of the affected skin",
      "Repeat mammogram after antibiotics",
      "Needle aspiration of fluid",
      "Breast MRI with contrast only"
    ],
    "answerIndex": 0,
    "rationale": "Persistent inflammatory changes raise concern for inflammatory breast cancer; punch biopsy can confirm dermal lymphatic invasion.",
    "wrongAnswerNotes": {
      "Repeat mammogram after antibiotics": "Delays diagnosis and may not detect dermal invasion.",
      "Needle aspiration of fluid": "Useful for abscess, not suspected IBC.",
      "Breast MRI with contrast only": "Adjunctive; tissue diagnosis is required."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "biopsy",
      "inflammatory breast cancer",
      "mammography",
      "mri"
    ]
  },
  {
    "id": "Q006",
    "stem": "Male patients with breast cancer are most likely to harbor which germline mutation?",
    "choices": [
      "PALB2",
      "MEN1",
      "BRCA2",
      "MLH1"
    ],
    "answerIndex": 2,
    "rationale": "BRCA2 is the mutation most strongly associated with male breast cancer.",
    "wrongAnswerNotes": {
      "PALB2": "Associated with breast cancer risk but less specifically with male cases than BRCA2.",
      "MEN1": "Related to endocrine neoplasia, not typical for male breast cancer.",
      "MLH1": "Mismatch repair gene linked to Lynch syndrome, not classic for male breast cancer."
    },
    "domain": "Nursing Practice",
    "tags": [
      "genetics",
      "oncologic emergency",
      "risk assessment",
      "symptom management"
    ]
  },
  {
    "id": "Q007",
    "stem": "A patient with a phyllodes tumor is most likely to experience hematogenous metastasis to which site if malignant?",
    "choices": [
      "Lung",
      "Brain",
      "Gallbladder",
      "Kidney"
    ],
    "answerIndex": 0,
    "rationale": "Malignant phyllodes tumors metastasize hematogenously, most commonly to the lungs.",
    "wrongAnswerNotes": {
      "Brain": "Possible but less common than lung.",
      "Gallbladder": "Not a typical site of spread.",
      "Kidney": "Not a typical site of spread."
    },
    "domain": "Nursing Practice",
    "tags": []
  },
  {
    "id": "Q008",
    "stem": "Which organization evaluates and accredits quality measures for breast centers (e.g., NAPBC)?",
    "choices": [
      "American College of Surgeons",
      "The Joint Commission",
      "Centers for Medicare & Medicaid Services",
      "Susan G. Komen"
    ],
    "answerIndex": 0,
    "rationale": "The American College of Surgeons administers NAPBC accreditation and quality standards for breast centers.",
    "wrongAnswerNotes": {
      "The Joint Commission": "Accredits hospitals broadly, not NAPBC-specific.",
      "Centers for Medicare & Medicaid Services": "Regulatory and reimbursement agency, not NAPBC.",
      "Susan G. Komen": "Advocacy and research funding, not accreditation."
    },
    "domain": "Nursing Practice",
    "tags": []
  },
  {
    "id": "Q009",
    "stem": "A colleague asks about the benefit of nursing certification. Which response best reflects certification?",
    "choices": [
      "“I have met predetermined standards for specialty practice.”",
      "“I am able to perform biopsies.”",
      "“It replaces state licensure.”",
      "“It increases reimbursement for services.”"
    ],
    "answerIndex": 0,
    "rationale": "Certification verifies specialized knowledge and practice standards; it does not replace licensure or independently expand scope.",
    "wrongAnswerNotes": {
      "“I am able to perform biopsies.”": "Scope of practice is regulated by licensure and institution, not certification alone.",
      "“It replaces state licensure.”": "Licensure is separate and required.",
      "“It increases reimbursement for services.”": "Certification does not directly change reimbursement."
    },
    "domain": "Nursing Practice",
    "tags": []
  },
  {
    "id": "Q010",
    "stem": "A 40-year-old is told her biopsy shows lobular carcinoma in situ (LCIS). She asks if this means she has cancer now. Best response?",
    "choices": [
      "“Yes, this is a type of cancer but doesn’t require treatment.”",
      "“No, it’s a high-risk marker that increases future invasive cancer risk.”",
      "“No, it’s benign; continue routine annual mammograms only.”",
      "“No, it will become cancer if not excised.”"
    ],
    "answerIndex": 1,
    "rationale": "Classic LCIS is a risk marker and non-obligate precursor; it increases future risk but is not an invasive cancer.",
    "wrongAnswerNotes": {
      "“Yes, this is a type of cancer but doesn’t require treatment.”": "Misclassifies LCIS as cancer.",
      "“No, it’s benign; continue routine annual mammograms only.”": "Risk-stratified counseling and surveillance are warranted.",
      "“No, it will become cancer if not excised.”": "Not an obligate precursor requiring excision."
    },
    "domain": "Nursing Practice",
    "tags": [
      "high-risk lesion",
      "lcis",
      "mammography",
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q011",
    "stem": "A 35-year-old scheduled for breast MRI says: “I’m worried about radiation.” Which statement signals misunderstanding?",
    "choices": [
      "“I will receive IV contrast for the test.”",
      "“I should remove all metal before the scan.”",
      "“MRI exposes me to radiation.”",
      "“MRI detects contrast-enhanced changes in tissue perfusion.”"
    ],
    "answerIndex": 2,
    "rationale": "MRI uses magnetic fields and radiofrequency—not ionizing radiation.",
    "wrongAnswerNotes": {
      "“I will receive IV contrast for the test.”": "Gadolinium contrast is typical for breast MRI.",
      "“I should remove all metal before the scan.”": "Correct MRI safety practice.",
      "“MRI detects contrast-enhanced changes in tissue perfusion.”": "Describes dynamic contrast-enhanced MRI principles."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "mri",
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q012",
    "stem": "A patient asks about features of Hereditary Breast and Ovarian Cancer (HBOC). Which is LEAST associated?",
    "choices": [
      "History of hormone replacement therapy",
      "Ashkenazi Jewish ancestry",
      "Male breast cancer in the family",
      "Multifocal breast cancer"
    ],
    "answerIndex": 0,
    "rationale": "HRT is a modifiable exposure, not a hallmark of HBOC; the others increase suspicion for BRCA-related syndromes.",
    "wrongAnswerNotes": {
      "Ashkenazi Jewish ancestry": "Founder mutations elevate risk.",
      "Male breast cancer in the family": "Raises suspicion for BRCA2.",
      "Multifocal breast cancer": "Associated with hereditary risk patterns."
    },
    "domain": "Nursing Practice",
    "tags": [
      "genetics",
      "oncologic emergency",
      "risk assessment",
      "symptom management"
    ]
  },
  {
    "id": "Q013",
    "stem": "While counseling a 60-year-old with HR+ disease about weight loss, which explanation is most accurate?",
    "choices": [
      "“After menopause, peripheral fat produces estrogen, increasing recurrence risk.”",
      "“Weight is the cause of all medical problems.”",
      "“Only a small amount of weight loss matters.”",
      "“If ovaries are removed, weight no longer affects risk.”"
    ],
    "answerIndex": 0,
    "rationale": "In postmenopausal women, aromatization in adipose tissue contributes to estrogen levels; excess adiposity is linked to recurrence.",
    "wrongAnswerNotes": {
      "“Weight is the cause of all medical problems.”": "Overgeneralization and inaccurate.",
      "“Only a small amount of weight loss matters.”": "Even modest loss helps, but statement is incomplete and minimizes risk.",
      "“If ovaries are removed, weight no longer affects risk.”": "Peripheral conversion remains relevant."
    },
    "domain": "Care Continuum",
    "tags": [
      "psychosocial"
    ]
  },
  {
    "id": "Q014",
    "stem": "Which statement best reflects the role of radiation after breast-conserving surgery (BCS) for early-stage breast cancer?",
    "choices": [
      "Reduces the risk of local recurrence in the treated breast",
      "Reduces systemic recurrence risk primarily",
      "Is indicated postmastectomy for tumors <4 cm without nodes",
      "Is not recommended in women >70 years"
    ],
    "answerIndex": 0,
    "rationale": "Whole-breast irradiation after BCS lowers ipsilateral breast tumor recurrence risk.",
    "wrongAnswerNotes": {
      "Reduces systemic recurrence risk primarily": "Local control is the main benefit.",
      "Is indicated postmastectomy for tumors <4 cm without nodes": "PMRT is risk-based; not automatic for small, node-negative tumors.",
      "Is not recommended in women >70 years": "May still be used depending on risk and preferences."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q015",
    "stem": "In obtaining a family history to assess genetic risk, which statement shows best understanding?",
    "choices": [
      "“I only need to report cancers.”",
      "“I’ll share all conditions on my mother’s side.”",
      "“I’ll provide cancers in first-degree relatives.”",
      "“I’ll find all diagnoses from both sides of my family.”"
    ],
    "answerIndex": 3,
    "rationale": "A comprehensive pedigree includes maternal and paternal sides and may include second-degree relatives to clarify patterns.",
    "wrongAnswerNotes": {
      "“I only need to report cancers.”": "Non-cancer diagnoses can inform syndromes.",
      "“I’ll share all conditions on my mother’s side.”": "Paternal side is equally important.",
      "“I’ll provide cancers in first-degree relatives.”": "Useful but incomplete; second-degree and both sides matter."
    },
    "domain": "Nursing Practice",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q016",
    "stem": "Which gene is most strongly associated with triple-negative breast cancer (TNBC)?",
    "choices": [
      "PALB2",
      "BRCA1",
      "BRCA2",
      "CDH1"
    ],
    "answerIndex": 1,
    "rationale": "BRCA1 is classically linked to TNBC phenotype.",
    "wrongAnswerNotes": {
      "PALB2": "Raises risk but less specifically linked to TNBC than BRCA1.",
      "BRCA2": "More commonly associated with HR+ tumors and male breast cancer.",
      "CDH1": "Related to hereditary diffuse gastric cancer and lobular breast cancer."
    },
    "domain": "Nursing Practice",
    "tags": [
      "genetics",
      "oncologic emergency",
      "risk assessment",
      "symptom management"
    ]
  },
  {
    "id": "Q017",
    "stem": "The nurse knows the patient did NOT understand leuprolide (GnRH agonist) teaching when she says:",
    "choices": [
      "“I will go into permanent medical menopause from the medication.”",
      "“My periods will stop while I’m receiving it.”",
      "“It suppresses estrogen production from my ovaries.”",
      "“It is given as an injection.”"
    ],
    "answerIndex": 0,
    "rationale": "Ovarian suppression with GnRH agonists is reversible; it does not cause permanent menopause.",
    "wrongAnswerNotes": {
      "“My periods will stop while I’m receiving it.”": "Amenorrhea is expected during therapy.",
      "“It suppresses estrogen production from my ovaries.”": "Mechanism is correct.",
      "“It is given as an injection.”": "Administration route is correct."
    },
    "domain": "Nursing Practice",
    "tags": []
  },
  {
    "id": "Q018",
    "stem": "A patient asks why you used the Gail Model while her cousin’s clinician used the Claus Model. Best explanation:",
    "choices": [
      "They are the same model with different names.",
      "One estimates breast cancer risk; the other predicts BRCA mutation probability.",
      "All models give the same output.",
      "Models are chosen based on individual personal and family-history features."
    ],
    "answerIndex": 3,
    "rationale": "Different models incorporate different variables; selection depends on a person’s age, reproductive history, and family patterns.",
    "wrongAnswerNotes": {
      "They are the same model with different names.": "They differ in inputs and outputs.",
      "One estimates breast cancer risk; the other predicts BRCA mutation probability.": "Not an accurate characterization of Gail vs Claus.",
      "All models give the same output.": "Outputs vary by model."
    },
    "domain": "Nursing Practice",
    "tags": [
      "genetics",
      "oncologic emergency",
      "risk assessment",
      "symptom management"
    ]
  },
  {
    "id": "Q019",
    "stem": "A 35-year-old tests BRCA2 positive. Her 25-year-old sister tests negative. Best counseling point?",
    "choices": [
      "“Your sister’s test was probably wrong; repeat it.”",
      "“She won’t develop breast cancer at all.”",
      "“She needs only routine screening with no additional measures.”",
      "“Siblings have up to a 50% chance of the mutation; your sister’s negative is possible, but she still needs age-appropriate screening.”"
    ],
    "answerIndex": 3,
    "rationale": "Autosomal dominant inheritance confers up to 50% risk; a negative sibling is plausible and should still follow general screening recommendations.",
    "wrongAnswerNotes": {
      "“Your sister’s test was probably wrong; repeat it.”": "No indication of lab error.",
      "“She won’t develop breast cancer at all.”": "Population risk remains.",
      "“She needs only routine screening with no additional measures.”": "Routine screening is appropriate, but counseling remains important."
    },
    "domain": "Psychosocial Dimensions",
    "tags": [
      "genetics",
      "oncologic emergency",
      "psychosocial",
      "risk assessment",
      "symptom management"
    ]
  },
  {
    "id": "Q020",
    "stem": "A patient on tamoxifen reports 3 months of intermenstrual spotting and cramping. Appropriate next step:",
    "choices": [
      "Reassure; bleeding is expected",
      "Check CBC only",
      "Gynecology referral for ultrasound ± endometrial biopsy",
      "Stop tamoxifen immediately and switch to AI"
    ],
    "answerIndex": 2,
    "rationale": "Tamoxifen increases risk of endometrial pathology; evaluation with pelvic ultrasound and possible biopsy is indicated.",
    "wrongAnswerNotes": {
      "Reassure; bleeding is expected": "Persistent or abnormal bleeding warrants evaluation.",
      "Check CBC only": "Does not evaluate endometrium.",
      "Stop tamoxifen immediately and switch to AI": "Switching is not first step without evaluation."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "chemoprevention",
      "endocrine therapy",
      "tamoxifen",
      "ultrasound"
    ]
  },
  {
    "id": "Q021",
    "stem": "What is the recommended systemic approach for a 1.3 cm, node-negative triple-negative breast cancer (TNBC)?",
    "choices": [
      "Hormonal therapy",
      "Chemotherapy",
      "Radiation therapy only",
      "Targeted anti-HER2 therapy"
    ],
    "answerIndex": 1,
    "rationale": "For TNBC ≥1 cm (T1c) or node-positive, adjuvant chemotherapy is recommended.",
    "wrongAnswerNotes": {
      "Hormonal therapy": "TNBC lacks hormone receptors.",
      "Radiation therapy only": "Local therapy does not address systemic risk in TNBC.",
      "Targeted anti-HER2 therapy": "TNBC is HER2-negative."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q022",
    "stem": "Which TNM category indicates direct extension to skin or chest wall in breast cancer?",
    "choices": [
      "T3",
      "M1",
      "M0",
      "T4"
    ],
    "answerIndex": 3,
    "rationale": "T4 designates skin/chest wall involvement (e.g., inflammatory changes or fixation).",
    "wrongAnswerNotes": {
      "T3": "Refers to tumor size >5 cm, not necessarily skin/chest wall involvement.",
      "M1": "Indicates distant metastasis.",
      "M0": "No distant metastasis."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "oncologic emergency",
      "staging",
      "symptom management"
    ]
  },
  {
    "id": "Q023",
    "stem": "Which biopsy technique is most appropriate for suspicious microcalcifications detected on mammography?",
    "choices": [
      "Fine-needle aspiration (FNA)",
      "Stereotactic core needle biopsy",
      "Duct excision",
      "MRI-guided core biopsy"
    ],
    "answerIndex": 1,
    "rationale": "Stereotactic core biopsy is standard for sampling mammographic calcifications.",
    "wrongAnswerNotes": {
      "Fine-needle aspiration (FNA)": "Often inadequate for calcifications.",
      "Duct excision": "Reserved for pathologic nipple discharge, not calcifications alone.",
      "MRI-guided core biopsy": "Used for MRI-only lesions."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "mammography",
      "microcalcifications",
      "mri",
      "stereotactic biopsy"
    ]
  },
  {
    "id": "Q024",
    "stem": "A 45-year-old with T2, node-negative HR+ breast cancer asks about recurrence risk tools. Best choice?",
    "choices": [
      "Breast MRI",
      "Oncotype DX assay",
      "PET/CT",
      "Screening ultrasound"
    ],
    "answerIndex": 1,
    "rationale": "Oncotype DX provides genomic risk stratification and chemotherapy benefit prediction in early-stage HR+/HER2– disease.",
    "wrongAnswerNotes": {
      "Breast MRI": "Imaging, not a genomic risk tool.",
      "PET/CT": "Not indicated for routine early-stage staging or risk estimation.",
      "Screening ultrasound": "Adjunct imaging, not a recurrence assay."
    },
    "domain": "Nursing Practice",
    "tags": [
      "mri",
      "oncologic emergency",
      "staging",
      "symptom management",
      "ultrasound"
    ]
  },
  {
    "id": "Q025",
    "stem": "A 28-year-old presents with a new palpable breast mass present for two weeks. Which initial imaging is most appropriate?",
    "choices": [
      "Diagnostic mammography",
      "Screening mammography",
      "Targeted breast ultrasound",
      "Breast MRI"
    ],
    "answerIndex": 2,
    "rationale": "In women under 30, targeted ultrasound is the preferred initial imaging for a palpable mass.",
    "wrongAnswerNotes": {
      "Diagnostic mammography": "Consider if ultrasound is suspicious or patient is ≥30–40.",
      "Screening mammography": "Screening is not the initial diagnostic test for a symptomatic mass.",
      "Breast MRI": "Not first-line for an initial palpable finding in this age group."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "mammography",
      "mri",
      "ultrasound"
    ]
  },
  {
    "id": "Q026",
    "stem": "A 71-year-old with a 0.9 cm, grade 1 ER+/HER2–, node-negative tumor undergoes lumpectomy. Which adjuvant systemic therapy is most appropriate?",
    "choices": [
      "Aromatase inhibitor therapy",
      "No therapy; observation",
      "Adjuvant chemotherapy followed by tamoxifen",
      "Tamoxifen plus ovarian suppression"
    ],
    "answerIndex": 0,
    "rationale": "Low-risk, small HR+ tumor after breast-conserving surgery warrants endocrine therapy; aromatase inhibitor is preferred postmenopausally.",
    "wrongAnswerNotes": {
      "No therapy; observation": "Endocrine therapy reduces recurrence even in low-risk disease.",
      "Adjuvant chemotherapy followed by tamoxifen": "Chemotherapy unlikely to add benefit in this setting.",
      "Tamoxifen plus ovarian suppression": "OFS is for premenopausal patients."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "chemoprevention",
      "endocrine therapy",
      "tamoxifen"
    ]
  },
  {
    "id": "Q027",
    "stem": "A 52-year-old with cT2N1 HER2+ cancer receives neoadjuvant taxane + trastuzumab/pertuzumab and has residual invasive disease at surgery. Best adjuvant plan?",
    "choices": [
      "Complete trastuzumab to one year",
      "Ado-trastuzumab emtansine for 14 cycles",
      "Pertuzumab monotherapy for 14 cycles",
      "Observation"
    ],
    "answerIndex": 1,
    "rationale": "Residual disease after neoadjuvant HER2 therapy warrants escalation to T-DM1 for 14 cycles to improve outcomes.",
    "wrongAnswerNotes": {
      "Complete trastuzumab to one year": "Appropriate after pCR; inferior with residual disease.",
      "Pertuzumab monotherapy for 14 cycles": "Not standard as single agent adjuvantly.",
      "Observation": "Undertreats residual disease."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "her2+",
      "oncologic emergency",
      "symptom management",
      "targeted therapy"
    ]
  },
  {
    "id": "Q028",
    "stem": "A 33-year-old with a new palpable mass at 3 o’clock, 2 cm from the nipple. Next best diagnostic step?",
    "choices": [
      "Targeted ultrasound of the palpable area",
      "Screening mammogram of both breasts",
      "Start antibiotics and re-evaluate in 2 weeks",
      "PET-CT to evaluate extent"
    ],
    "answerIndex": 0,
    "rationale": "For women <30–35 with a focal mass, targeted ultrasound is the best initial diagnostic test.",
    "wrongAnswerNotes": {
      "Screening mammogram of both breasts": "Screening is not diagnostic for a new symptom.",
      "Start antibiotics and re-evaluate in 2 weeks": "No erythema/abscess features; delays diagnosis.",
      "PET-CT to evaluate extent": "Not first-line for initial work-up."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "mammography",
      "ultrasound"
    ]
  },
  {
    "id": "Q029",
    "stem": "Which patient is most appropriate for risk-reducing tamoxifen chemoprevention?",
    "choices": [
      "Premenopausal woman with elevated 5-year invasive risk on Gail model",
      "Postmenopausal woman with normal BMD on aromatase inhibitor",
      "Male with BRCA2 mutation",
      "Woman with active DVT on anticoagulation"
    ],
    "answerIndex": 0,
    "rationale": "Tamoxifen reduces invasive ER+ risk and is an option for high-risk premenopausal women.",
    "wrongAnswerNotes": {
      "Postmenopausal woman with normal BMD on aromatase inhibitor": "AIs can be used for chemoprevention postmenopausally; the prompt asks specifically for tamoxifen.",
      "Male with BRCA2 mutation": "Risk-reducing mastectomy and screening discussed; tamoxifen chemoprevention is not typical.",
      "Woman with active DVT on anticoagulation": "Tamoxifen contraindicated due to VTE risk."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "chemoprevention",
      "endocrine therapy",
      "genetics",
      "risk assessment",
      "tamoxifen"
    ]
  },
  {
    "id": "Q030",
    "stem": "A patient after ALND develops tight, painful cord-like bands in the axilla and medial arm limiting abduction. This is most consistent with:",
    "choices": [
      "Axillary web syndrome (cording)",
      "Lymphedema",
      "Brachial plexopathy",
      "Cellulitis"
    ],
    "answerIndex": 0,
    "rationale": "Axillary web syndrome presents with palpable, painful cords limiting ROM after nodal surgery.",
    "wrongAnswerNotes": {
      "Lymphedema": "Characterized by swelling, heaviness, and pitting/firm edema, not cords.",
      "Brachial plexopathy": "Neuropathic pain/weakness, not palpable cords.",
      "Cellulitis": "Erythema, warmth, systemic signs of infection."
    },
    "domain": "Nursing Practice",
    "tags": [
      "symptom management"
    ]
  },
  {
    "id": "Q031",
    "stem": "Following breast-conserving surgery, which margin status generally warrants re-excision for invasive cancer?",
    "choices": [
      "Tumor on ink",
      "2 mm clear margin",
      "5 mm clear margin",
      "No DCIS at the margin but 1 mm from ink"
    ],
    "answerIndex": 0,
    "rationale": "For invasive cancer, 'no ink on tumor' is adequate; tumor on ink warrants re-excision.",
    "wrongAnswerNotes": {
      "2 mm clear margin": "Adequate for invasive disease (no ink on tumor).",
      "5 mm clear margin": "Adequate margin.",
      "No DCIS at the margin but 1 mm from ink": "Still acceptable if no ink on tumor."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q032",
    "stem": "Which finding on pathology most strongly suggests a need to consider adjuvant bisphosphonates in a postmenopausal HR+ patient?",
    "choices": [
      "Osteopenia or osteoporosis on DEXA",
      "Micrometastatic nodal disease",
      "High Ki-67 index",
      "Lymphovascular invasion"
    ],
    "answerIndex": 0,
    "rationale": "Bone-modifying agents may be used to protect bone health during AI therapy and may reduce recurrence in postmenopausal women.",
    "wrongAnswerNotes": {
      "Micrometastatic nodal disease": "Affects systemic therapy choices but not bisphosphonate indication directly.",
      "High Ki-67 index": "Proliferation marker; does not drive bone therapy decision alone.",
      "Lymphovascular invasion": "Prognostic but not a direct bisphosphonate trigger."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "bone health"
    ]
  },
  {
    "id": "Q033",
    "stem": "A 58-year-old on aromatase inhibitor therapy reports new hip pain and T-score of −2.6. Best intervention:",
    "choices": [
      "Start IV zoledronic acid or SC denosumab with calcium/vitamin D",
      "Stop AI and switch to tamoxifen",
      "Start NSAIDs only",
      "Order PET-CT to rule out metastasis immediately"
    ],
    "answerIndex": 0,
    "rationale": "AI therapy can accelerate bone loss; osteoporosis (T ≤ −2.5) warrants antiresorptive therapy plus Ca/Vit D and weight-bearing exercise.",
    "wrongAnswerNotes": {
      "Stop AI and switch to tamoxifen": "Consider only if intolerable toxicity; bone-directed agents are first-line for osteoporosis.",
      "Start NSAIDs only": "Symptomatic relief without addressing bone loss.",
      "Order PET-CT to rule out metastasis immediately": "Assess clinically first; osteoporosis is sufficient indication for bone agents."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "bone health",
      "chemoprevention",
      "endocrine therapy",
      "tamoxifen"
    ]
  },
  {
    "id": "Q034",
    "stem": "Which statement about BIRADS 3 (Probably Benign) is most accurate?",
    "choices": [
      "Short-interval imaging follow-up is recommended",
      "Biopsy is mandated",
      "Return to routine annual screening",
      "Immediate MRI is indicated"
    ],
    "answerIndex": 0,
    "rationale": "BIRADS 3 lesions have <2% risk of malignancy; 6-month follow-up is typical.",
    "wrongAnswerNotes": {
      "Biopsy is mandated": "Reserved for BIRADS 4–5.",
      "Return to routine annual screening": "Too long an interval for BIRADS 3.",
      "Immediate MRI is indicated": "Not standard for probably benign findings."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "birads",
      "mri"
    ]
  },
  {
    "id": "Q035",
    "stem": "A 49-year-old with cT2N0 triple-negative disease is planned for neoadjuvant therapy. Preferred regimen includes:",
    "choices": [
      "Pembrolizumab with taxane + platinum, followed by anthracycline",
      "Capecitabine monotherapy",
      "Docetaxel/cyclophosphamide x 4 cycles",
      "Tamoxifen for 5 years"
    ],
    "answerIndex": 0,
    "rationale": "Stage II–III TNBC: add pembrolizumab to taxane/platinum then anthracycline, with adjuvant pembrolizumab completion.",
    "wrongAnswerNotes": {
      "Capecitabine monotherapy": "Used adjuvantly for residual disease, not as sole neoadjuvant.",
      "Docetaxel/cyclophosphamide x 4 cycles": "May be used adjuvantly but not preferred with IO for stage II–III TNBC.",
      "Tamoxifen for 5 years": "TNBC is hormone receptor negative."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "anthracycline",
      "cardiotoxicity",
      "chemoprevention",
      "endocrine therapy",
      "immunotherapy",
      "tamoxifen",
      "tnbc"
    ]
  },
  {
    "id": "Q036",
    "stem": "A patient receiving paclitaxel develops numbness and tingling in the feet interfering with sleep. Best initial management includes:",
    "choices": [
      "Dose hold or reduction and symptomatic measures",
      "High-dose corticosteroids",
      "Empiric antibiotics",
      "Immediate chemotherapy discontinuation permanently"
    ],
    "answerIndex": 0,
    "rationale": "Taxanes can cause peripheral neuropathy; dose modification and symptomatic care are first steps.",
    "wrongAnswerNotes": {
      "High-dose corticosteroids": "Not indicated for chemotherapy-induced neuropathy.",
      "Empiric antibiotics": "No infection signs.",
      "Immediate chemotherapy discontinuation permanently": "Consider only if severe/refractory."
    },
    "domain": "Nursing Practice",
    "tags": [
      "symptom management"
    ]
  },
  {
    "id": "Q037",
    "stem": "A lactating 29-year-old presents with fever, erythema, and focal fluctuance. First-line diagnostic/therapeutic step:",
    "choices": [
      "Ultrasound-guided aspiration and culture",
      "Diagnostic mammography",
      "MRI with contrast",
      "Empiric chemotherapy"
    ],
    "answerIndex": 0,
    "rationale": "Findings suggest breast abscess; ultrasound confirms and guides aspiration/drainage and culture.",
    "wrongAnswerNotes": {
      "Diagnostic mammography": "Limited utility in acute lactational abscess.",
      "MRI with contrast": "Not first-line for suspected abscess.",
      "Empiric chemotherapy": "Not indicated."
    },
    "domain": "Nursing Practice",
    "tags": [
      "mammography",
      "mri",
      "oncologic emergency",
      "symptom management",
      "ultrasound"
    ]
  },
  {
    "id": "Q038",
    "stem": "Which patient scenario most strongly warrants referral for genetic counseling/testing?",
    "choices": [
      "Triple-negative breast cancer at age 38",
      "ER+ grade 1 tumor at age 72",
      "Solitary fibroadenoma at age 26",
      "Atypical ductal hyperplasia at age 58"
    ],
    "answerIndex": 0,
    "rationale": "TNBC diagnosed under age 60 meets common criteria for germline testing.",
    "wrongAnswerNotes": {
      "ER+ grade 1 tumor at age 72": "Age and subtype confer lower suspicion absent strong family history.",
      "Solitary fibroadenoma at age 26": "Benign; does not indicate testing by itself.",
      "Atypical ductal hyperplasia at age 58": "Raises risk but not a direct indication without other factors."
    },
    "domain": "Psychosocial Dimensions",
    "tags": [
      "oncologic emergency",
      "psychosocial",
      "symptom management"
    ]
  },
  {
    "id": "Q039",
    "stem": "A patient receiving doxorubicin/cyclophosphamide (AC) asks about hair loss. Best counseling:",
    "choices": [
      "Alopecia is common; scalp cooling may reduce risk if available",
      "Alopecia is rare with AC",
      "Minoxidil prevents chemotherapy-induced alopecia",
      "Shaving the head prevents alopecia"
    ],
    "answerIndex": 0,
    "rationale": "AC frequently causes alopecia; scalp cooling can lower incidence/severity in some settings.",
    "wrongAnswerNotes": {
      "Alopecia is rare with AC": "Incorrect; it is common.",
      "Minoxidil prevents chemotherapy-induced alopecia": "May aid regrowth but does not prevent CIA.",
      "Shaving the head prevents alopecia": "Does not prevent follicular damage."
    },
    "domain": "Nursing Practice",
    "tags": [
      "alopecia",
      "anthracycline",
      "cardiotoxicity",
      "psychosocial"
    ]
  },
  {
    "id": "Q040",
    "stem": "After sentinel lymph node biopsy, a patient reports shoulder stiffness and limited abduction. Best early intervention:",
    "choices": [
      "Early range-of-motion exercises and PT referral",
      "Prolonged sling immobilization",
      "High-intensity resistance training immediately",
      "Wait 6–8 weeks before movement"
    ],
    "answerIndex": 0,
    "rationale": "Early gentle ROM prevents adhesive capsulitis and improves function; PT can guide recovery.",
    "wrongAnswerNotes": {
      "Prolonged sling immobilization": "Increases stiffness risk.",
      "High-intensity resistance training immediately": "Progress gradually; start with gentle ROM.",
      "Wait 6–8 weeks before movement": "Delays recovery and increases stiffness risk."
    },
    "domain": "Nursing Practice",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q041",
    "stem": "Which finding most strongly supports pathologic complete response (pCR) after neoadjuvant therapy in TNBC/HER2+ disease?",
    "choices": [
      "No residual invasive or in situ cancer in breast and nodes",
      "Negative margins on lumpectomy",
      "Absence of skin changes",
      "Normal postoperative CA 15-3 level"
    ],
    "answerIndex": 0,
    "rationale": "pCR is defined by absence of residual invasive and in situ cancer in breast and nodes (ypT0/Tis ypN0).",
    "wrongAnswerNotes": {
      "Negative margins on lumpectomy": "Does not define pCR.",
      "Absence of skin changes": "Not a pCR criterion.",
      "Normal postoperative CA 15-3 level": "Tumor markers are not used to define pCR."
    },
    "domain": "Nursing Practice",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q042",
    "stem": "A 64-year-old with ER+/HER2– stage IIA disease is intolerant of aromatase inhibitors due to severe arthralgias. Reasonable endocrine approach:",
    "choices": [
      "Switch to tamoxifen and continue planned duration",
      "Stop endocrine therapy entirely",
      "Add prednisone chronically to tolerate AI",
      "Switch to fulvestrant monotherapy in adjuvant setting"
    ],
    "answerIndex": 0,
    "rationale": "Switching to tamoxifen is reasonable if AI intolerance occurs; continuing endocrine therapy is important.",
    "wrongAnswerNotes": {
      "Stop endocrine therapy entirely": "Increases recurrence risk unnecessarily.",
      "Add prednisone chronically to tolerate AI": "Chronic steroids not appropriate for AI arthralgias.",
      "Switch to fulvestrant monotherapy in adjuvant setting": "Not standard adjuvant endocrine therapy."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "chemoprevention",
      "endocrine therapy",
      "symptom management",
      "tamoxifen"
    ]
  },
  {
    "id": "Q043",
    "stem": "Which postoperative finding after mastectomy with immediate implant reconstruction warrants urgent surgical evaluation?",
    "choices": [
      "Progressive skin flap dusky discoloration with cool temperature",
      "Mild peri-incisional ecchymosis",
      "Serous drain output of 40 mL/day",
      "Tightness sensation over the implant pocket"
    ],
    "answerIndex": 0,
    "rationale": "Signs of compromised perfusion (dusky, cool flaps) suggest ischemia/necrosis and need urgent evaluation.",
    "wrongAnswerNotes": {
      "Mild peri-incisional ecchymosis": "Expected postoperative change.",
      "Serous drain output of 40 mL/day": "Within expected range.",
      "Tightness sensation over the implant pocket": "Common early postoperative sensation."
    },
    "domain": "Nursing Practice",
    "tags": []
  },
  {
    "id": "Q044",
    "stem": "A 56-year-old with HR+/HER2– metastatic disease develops progressive hot flashes on venlafaxine. Which medication should be avoided with tamoxifen?",
    "choices": [
      "Paroxetine",
      "Gabapentin",
      "Clonidine",
      "Citalopram (low dose)"
    ],
    "answerIndex": 0,
    "rationale": "Paroxetine strongly inhibits CYP2D6, reducing tamoxifen activation.",
    "wrongAnswerNotes": {
      "Gabapentin": "Alternative for vasomotor symptoms without CYP2D6 inhibition.",
      "Clonidine": "Alternative option in some patients.",
      "Citalopram (low dose)": "Weaker CYP2D6 inhibition than paroxetine/fluoxetine."
    },
    "domain": "Nursing Practice",
    "tags": [
      "chemoprevention",
      "endocrine therapy",
      "symptom management",
      "tamoxifen"
    ]
  },
  {
    "id": "Q045",
    "stem": "Which perioperative lymphedema risk reduction strategy is most appropriate after axillary surgery?",
    "choices": [
      "Early, gradual compression sleeve fitting if swelling develops",
      "Avoid all blood pressure cuffs and venipuncture for life",
      "High-intensity upper limb exercise immediately",
      "Diuretics at first sign of swelling"
    ],
    "answerIndex": 0,
    "rationale": "Compression and early rehab are evidence-based; strict lifetime bans on BP/venipuncture are not strongly supported.",
    "wrongAnswerNotes": {
      "Avoid all blood pressure cuffs and venipuncture for life": "Not necessary in all cases; individualized.",
      "High-intensity upper limb exercise immediately": "Progress activity gradually.",
      "Diuretics at first sign of swelling": "Not effective for lymphatic fluid."
    },
    "domain": "Nursing Practice",
    "tags": [
      "symptom management"
    ]
  },
  {
    "id": "Q046",
    "stem": "A patient with metastatic HR+/HER2– disease on aromatase inhibitor + CDK4/6 inhibitor reports new grade 3 neutropenia. Best next step:",
    "choices": [
      "Hold CDK4/6 inhibitor and resume at reduced dose per protocol",
      "Stop all therapy permanently",
      "Add prophylactic antibiotics lifelong",
      "Switch immediately to chemotherapy"
    ],
    "answerIndex": 0,
    "rationale": "CDK4/6-related neutropenia is managed by dose holds and reductions; febrile risk is lower than with cytotoxic chemo.",
    "wrongAnswerNotes": {
      "Stop all therapy permanently": "Unnecessary; dose modify first.",
      "Add prophylactic antibiotics lifelong": "Not indicated without recurrent infections.",
      "Switch immediately to chemotherapy": "Reserve for progression or intolerance despite adjustments."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "aromatase inhibitor",
      "cdk4/6 inhibitor",
      "endocrine therapy"
    ]
  },
  {
    "id": "Q047",
    "stem": "Which survivorship recommendation is MOST appropriate for a postmenopausal woman with prior left-sided radiation?",
    "choices": [
      "Assess cardiac risk factors and consider periodic echocardiography if symptomatic",
      "Routine PET-CT annually to detect recurrence",
      "Chronic anticoagulation to prevent radiation-induced thrombosis",
      "Avoid all exercise to protect the heart"
    ],
    "answerIndex": 0,
    "rationale": "Cardiovascular monitoring is important after left-sided radiation; imaging is symptom-directed.",
    "wrongAnswerNotes": {
      "Routine PET-CT annually to detect recurrence": "Not recommended for surveillance in asymptomatic survivors.",
      "Chronic anticoagulation to prevent radiation-induced thrombosis": "Not indicated.",
      "Avoid all exercise to protect the heart": "Exercise is beneficial; tailor to fitness and comorbidities."
    },
    "domain": "Care Continuum",
    "tags": [
      "anthracycline",
      "cardiotoxicity"
    ]
  },
  {
    "id": "Q048",
    "stem": "A patient calls 6 days after chemotherapy with fever 38.8°C (101.8°F), chills, and ANC 500/mm³. Best disposition:",
    "choices": [
      "Immediate hospital evaluation for febrile neutropenia",
      "Oral antibiotics at home and follow-up in 48 hours",
      "Increase fluid intake and rest",
      "Wait for CBC to normalize"
    ],
    "answerIndex": 0,
    "rationale": "Febrile neutropenia (ANC ≤500 with fever) is an oncologic emergency requiring prompt evaluation and IV empiric antibiotics.",
    "wrongAnswerNotes": {
      "Oral antibiotics at home and follow-up in 48 hours": "Under-treatment and unsafe.",
      "Increase fluid intake and rest": "Delays critical care.",
      "Wait for CBC to normalize": "Dangerous delay."
    },
    "domain": "Nursing Practice",
    "tags": [
      "oncologic emergency",
      "symptom management"
    ]
  },
  {
    "id": "Q049",
    "stem": "Which psychosocial intervention best supports a patient with new body image distress after mastectomy?",
    "choices": [
      "Offer peer-support groups and referral to counseling",
      "Reassure that distress is normal; no action needed",
      "Avoid discussing feelings to prevent rumination",
      "Recommend immediate tattooing before healing"
    ],
    "answerIndex": 0,
    "rationale": "Peer support and counseling are evidence-based for coping and adjustment.",
    "wrongAnswerNotes": {
      "Reassure that distress is normal; no action needed": "Validation helps, but active support is better.",
      "Avoid discussing feelings to prevent rumination": "Avoidance worsens distress.",
      "Recommend immediate tattooing before healing": "Timing and readiness should be assessed later."
    },
    "domain": "Psychosocial Dimensions",
    "tags": [
      "psychosocial"
    ]
  },
  {
    "id": "Q050",
    "stem": "Which teaching is MOST appropriate to reduce radiation dermatitis during whole-breast irradiation?",
    "choices": [
      "Gentle washing, moisturizers, avoid friction/heat, and report moist desquamation",
      "Daily exfoliation with loofah to remove flaky skin",
      "Ice packs directly on irradiated skin",
      "Topical antibiotics routinely for prevention"
    ],
    "answerIndex": 0,
    "rationale": "Skin care includes gentle cleansing, moisturizers, minimizing friction/heat, and prompt reporting of moist desquamation for management.",
    "wrongAnswerNotes": {
      "Daily exfoliation with loofah to remove flaky skin": "Can worsen irritation.",
      "Ice packs directly on irradiated skin": "May injure skin and is not recommended.",
      "Topical antibiotics routinely for prevention": "Use only if infected, not prophylactically."
    },
    "domain": "Nursing Practice",
    "tags": [
      "symptom management"
    ]
  }
]